Attovia Therapeutics

📍 San Carlos, United States🗓 Founded 2023👥 53 employees💰 Last funded Apr 2025
Biotechnology Research🌐 attovia.com
Website LinkedIn
Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY™, our proprietary biologics platform, to generate potentially first-in-class and best-in-class multi-specifics. ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES results in ultra-high affinity, which translates to best-in-class potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of multi-specific biologics, with tunable half-life translating to the potential for quarterly or less frequent dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development, offering the potential to become the next-generation modality of choice. Learn more at www.attovia.com.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
China
1
Investor activity2023–2025 · investors recorded per year
202312024120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Attovia Therapeutics?
Attovia Therapeutics has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Attovia Therapeutics last raise funding?
The most recent investment in Attovia Therapeutics recorded on gritt.io was in April 2025.
When was Attovia Therapeutics founded?
Attovia Therapeutics was founded in 2023.
What industry is Attovia Therapeutics in?
Attovia Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Attovia Therapeutics based?
Attovia Therapeutics is headquartered in San Carlos, United States.